|
5th International AIDS Society Conference on HIV Pathogenesis and TreatmentCape Town - July 19 - 22, 2009 |
CORONARY VASOMOTOR FUNCTION IS REDUCED AFTER INITIATION OF ANTIRETROVIRAL THERAPY IN TREATMENT NAÏVE HIV PATIENTS: A PROSPECTIVE MYOCARDIAL PERFUSION PET STUDY
IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: Abstract No. MOAB205
U.S. Kristoffersen
1,2, A.-M. Lebech3, J. Gerstoft4, N. Wiinberg5, H. Gutte1,2, C.L. Petersen5, A. Kjaer1,2
1Copenhagen University Hospital, Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine & PET, Copenhagen, Denmark, 2University of Copenhagen, Cluster for Molecular Imaging, Copenhagen, Denmark, 3Hvidovre University Hospital, Department of Infectious Diseases, Copenhagen, Denmark, 4Copenhagen University Hospital, Rigshospitalet, Department of Infectious Diseases, Copenhagen, Denmark, 5Frederiksberg Hospital, Department of Clinical Physiology and Nuclear Medicine, Copenhagen, Denmark
BACKGROUND: Recent observational studies have shown antiretroviral therapy (ART) to be associated with increased risk of cardiovascular disease (CVD) in HIV patients. However, a causal connection between ART and CVD remains undiscovered. The aim of the present study was, in a prospective design, to investigate if coronary vasomotor function changed in treatment naïve HIV patients when ART was initiated.
METHODS: Myocardial perfusion was assessed by 13N-NH3 positron emission tomography (PET) scans before and one month after initiation of ART in ten treatment naïve HIV patients. At both examinations, the baseline myocardial perfusion, the perfusion during cold pressor testing (left foot in 0°C water), and the maximal hyperaemic perfusion after a pharmalogical stress with dypyridamol (0.56 mg/kg body weight) were determined. A normalized baseline perfusion was obtained by dividing the perfusion at rest with the pulse pressure product and multiplying with 10,000. The myocardial flow reserve (MFR) was calculated by dividing the maximal hyperaemic perfusion with the baseline perfusion and the cold pressor reserve (CPR) was calculated by dividing the perfusion during cold pressor testing with the baseline perfusion. Data from before and after ART initiation were compared with paired t-tests and p<0.05 was considered significant.
RESULTS: Maximal hyperaemic perfusion decreased from 2.3±0.26 to 1.7±0.16 mL/g/min after initiation of ART (p=0.021). No changes were observed in normalized baseline perfusion (1.2±0.07 to 1.1±0.05 mL/g/min), CPR (1.2±0.08 to 1.2 ±0.05), or MFR (2.7±0.28 to 2.4±0.23).
CONCLUSIONS: Coronary vasomotor function was compromised by a decrease in maximal hyperaemic perfusion one month after initiation of ART in treatment naïve HIV patients. These findings indicate causality between ART initiation and impaired vasomotor function and thus support the findings of increased risk of CVD in recently presented observational studies. Additionally, no change was observed in CPR, suggesting other responsible mechanisms than those typical for endothelial dysfunction.
Download PDF of this abstract.
Download Power Point Presentation.
2009-07-22
MOAB205
Oral Abstract Session MOAB2 - Cardiovascular Disease: to HAART or not to HAART
Copyright © 2009 - International AIDS Society (IAS). All information and content relating to the abstracts from the 5th International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, AIDS Walk of Orange County, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.